Session (CTI)

Issue: Addressing the untapped potential of Comprehensive Genomic Profiling (CGP) in tumour characterisation and treatment decision-making for cancer patients. The European Coalition for Access to Comprehensive Genomic Profiling (ECGP) recently published a report on this topic. CGP is revolutionizing tumour diagnostics by consolidating multiple tests into a single, comprehensive next-generation sequencing (NGS) assay, uncovering a wide range of genomic alterations/signatures that drive cancer growth. Despite ESMO’s recommendations, access to broad molecular diagnostics, including CGP, remains inconsistent and limited across Europe, highlighting a critical gap in equitable cancer care. This session will discuss how best to facilitate patient access to CGP, via case studies that show potential impact; leading to the development of clear recommendations following consensus-building discussion. Discussion plan: Opening, introduction panellists and overview of ECGP by Alexander Natz (10 minutes). Moderated discussion by panellist (30 minutes) on the preconditions for patient access. Discussion is brought to life with a series of case studies (at European or national level). These case studies underscore the commitment of policymakers to expand patient access to diagnostic technologies. However, there is room for improvement. Focus of this discussion will be on key enablers regarding: 1) Funding, assessment and reimbursement; and 2) Data and infrastructure needs to implement requirements. During this discussion, the panellists will provide insights from diverse perspectives; representing HCPs, the health economic dividend and payer perspective. Q&A with the audience and key actions will be the closing of the session (15 minutes).